Translational Pediatrics and Infectious Diseases Section, Pediatrics Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain.
School of Population and Global Health, The University of Melbourne, and Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
Hum Vaccin Immunother. 2019;15(12):2940-2951. doi: 10.1080/21645515.2019.1627159. Epub 2019 Jul 9.
The multicomponent meningococcal serogroup B vaccine, 4CMenB, has demonstrated effectiveness in preventing invasive MenB disease in infants and in controlling MenB outbreaks. The need for/timing of additional booster doses is not yet established. We reviewed eight studies that evaluated antibody persistence and booster following primary 4CMenB vaccination of infants, children, adolescents, and young adults. Putative seroprotective hSBA titers for ≥1 vaccine antigen were maintained by 76-100% of children 24-36 months after priming during infancy and in 84-100% after priming in the second year of life. hSBA levels were higher in vaccinees at 4 and 7.5 years following priming during adolescence than in vaccine-naïve individuals of a similar age. Antibodies persisted at higher levels to NHBA and NadA than to PorA or fHbp. Booster vaccination induced robust anamnestic responses, demonstrating effective priming by 4CMenB across age-groups. These data can inform decision-making to optimize vaccination strategies.
四价脑膜炎球菌结合疫苗（4CMenB）在预防婴儿侵袭性 B 群脑膜炎奈瑟菌病和控制 B 群脑膜炎奈瑟菌暴发方面显示出有效性。然而，是否需要/何时需要额外的加强剂量还尚未确定。我们回顾了 8 项研究，这些研究评估了婴儿、儿童、青少年和年轻人初次接种 4CMenB 疫苗后的抗体持久性和加强免疫。在婴儿期初次接种后 24-36 个月，以及在第二年再次接种后，有 76-100%的儿童可维持针对≥1 种疫苗抗原的假定血清保护性 hSBA 滴度。在青春期初次接种 4 年和 7.5 年后，疫苗接种者的 hSBA 水平高于相似年龄的疫苗初免者。与 PorA 或 fHbp 相比，NHBA 和 NadA 的抗体持久性更高。加强免疫可诱导出强烈的记忆应答，证明 4CMenB 可在各年龄段有效引发初次免疫。这些数据可用于决策优化疫苗接种策略。
